Skip to main content
. 2020 Jul 16;13(7):e235774. doi: 10.1136/bcr-2020-235774

Figure 1.

Figure 1

Central hepatic metastasis indicated by the arrow at 2 months (A), 10 months (B) and 35 months (C) after starting pembrolizumab. This lesion has had a sustained response to pembrolizumab. Left lateral hepatic metastasis 2 months (D), 10 months (E) and 35 months (F) after starting pembrolizumab. This lesion was treated with stereotactic body radiotherapy (SBRT) 11 months after starting pembrolizumab and has had a sustained response after SBRT. Fiducial placed for SBRT seen in (F).